Navigation Links
5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC
Date:11/6/2008

WHAT: The Fifth International Conference on Cell Therapy for Cardiovascular Disease (IC3D) is a three-day comprehensive program dedicated to the evolving field of cell-based therapies for treating cardiovascular diseases. The theme of this year's meeting is "Cellular and Molecular Building Blocks: Strategies for Cardiovascular Reconstruction in 2009."

WHY: Leaders in the field will convene to present basic, core discussions on stem cell science as well as their work, experiences, observations, and opinions on the benefits and drawbacks of the field. The 2009 meeting will encompass a broad range of cell-based therapeutic approaches to cardiovascular disease.

Research presented at IC3D will touch on topics such as:

  • Clinical studies of stem cell repair of the heart, brain and peripheral arteries
  • New sources of adult stem cells
  • Status of embryonic stem cell research
  • Molecular signaling and cellular responses
  • Models of acute and chronic myocardial injury
  • Methods for application of stem cell products
  • Engineered tissue including in vitro and in vivo studies
  • Imaging and other assessment methods

New sessions for 2009 will include:

  • Focus on peripheral vascular disease
  • An in-depth view of stem cell effects and how to best assess disease states
  • The convergence of cell and tissue modification as methods for enhancing the biologic effects of molecular and cellular agents

WHO: Warren Sherman, M.D., Conference Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patient's own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.

WHEN: January 13 16, 2008

WHERE: The New York Academy of Medicine, New York, NY


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
2. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
3. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
4. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
5. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
6. Annual flu shot cuts need for doctors visits, hospitalization among children
7. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
8. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
9. Chem Rx to Present at Bear Stearns 20th Annual Healthcare Conference
10. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
11. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... HIMSS ... will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s foremost ... Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, The ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: ... a major advancement in drug therapy for patients living with relapsing and primary ... a novel B cell targeted therapy that has been proven to significantly reduce ...
(Date:7/26/2017)... ... July 26, 2017 , ... A major challenge many labs ... freeze drying samples and a lengthy freeze dry cycle are a few common challenges ... drying techniques, as well as new accessories and advancements in laboratory freeze dryers that ...
(Date:7/26/2017)... ... July 26, 2017 , ... The ... Process Validation and Process Validation Statistics Conferences in Bethesda, Maryland, 12 – ... challenges faced by process validation professionals and statisticians today. , “These conferences ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Team Type ... access to medicine for everyone affected by diabetes, is excited to announce the 106 ... Global Ambassador Program. , Established in 2005, the Team Type 1 Foundation has ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
(Date:7/10/2017)... The Institute for In Vitro Sciences (IIVS), ... of a VITROCELL® inhalation exposure system thanks to a ... device, which is designed to replace animals in inhalation ... to airborne test materials in an environment that mimics ... for testing combustible tobacco products, as well as next ...
(Date:7/10/2017)...  The tenth annual BioPharm America™ will ... at the Sheraton Boston Hotel, September 26–27. The event ... decision makers and innovative biotech startup companies. The event ... two impactful days. BioPharm America is now part of ... opportunities with 4,500+ life science industry influencers participating in ...
Breaking Medicine Technology: